Clinical Trials Logo
  1. Home
  2. Shock, Septic
  3. NCT02716597

Effect of Albumin Administration on Vasopressor Duration in Resolving Septic Shock

Shock, Septic Clinical Trial

Official title:
Effect of Albumin Administration on Vasopressor Duration in Resolving Septic Shock

Clinical Trial Summary

The role of albumin in sepsis has been controversial for decades. Although hypoalbuminemia has been associated with worse outcomes in sepsis, definitive evidence does not exist that replacing albumin in these patients improves outcomes. However, subgroup analyses from large clinical trials indicate that albumin may reduce mortality in septic shock, and in particular, may reduce the time a patient requires vasopressor support. Given this background, we are conducting this study to evaluate the role of albumin replacement in the patient with resolving septic shock to determine if albumin administration reduces the time a patient requires vasopressor support, reduces the time required for central line, and ultimately whether any potential benefit in terms of reduction of vasopressor support is associated with ICU length of stay and other outcomes. The approach is unique from larger trials of albumin in that it is a septic shock study geared at a particular phenotype of the patient in septic shock and evaluating a specific intervention at a specific time point in the course of septic shock.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02716597
Study type Interventional
Source University of Kentucky
Contact
Status Terminated
Phase Phase 1
Start date March 2016
Completion date January 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03592693 - Vitamin C, Hydrocortisone and Thiamine for Septic Shock Phase 2
Terminated NCT01639664 - COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2 N/A
Withdrawn NCT01601938 - Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients Phase 2
Recruiting NCT00335907 - Protocol-driven Hemodynamic Support for Patients With Septic Shock N/A
Completed NCT00000574 - Ibuprofen in Sepsis Study Phase 3
Recruiting NCT04910841 - Feasibility of Using the "CGM GUARDIAN 2" Interstitial Fluid Glucose Measurement System in Intensive Care Medicine N/A
Active, not recruiting NCT04079829 - Postoperative Respiratory Abnormalities
Recruiting NCT04569942 - Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis Phase 3
Recruiting NCT04934943 - "Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools"
Completed NCT01310790 - Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock Phase 4
Completed NCT00241228 - Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care) N/A
Completed NCT00046072 - A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis Phase 2
Withdrawn NCT03122678 - Thiamine Supplementation in Patients With Septic Shock Phase 1
Recruiting NCT06155812 - Multimodal Vasopressor Strategy in Septic Shock Phase 2/Phase 3
Completed NCT04178148 - Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock N/A
Completed NCT01453270 - Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial N/A
Completed NCT04576819 - Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis
Active, not recruiting NCT04055909 - Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock Phase 2
Suspended NCT03193164 - Neuromuscular Electrical Stimulation and Septic Shock N/A
Completed NCT04647552 - Effects of Hydrocortison Treatment on Angiotensin II and Angiotensin II Receptors in Patients With Septic Shock